Moderna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street's expectations for the second quarter as it works to cut costs.Shares of Moderna fell more than 4% in premarket trading on Friday.The biotech company now expects full-year revenue to come in between $1.5 billion and$2.2 billion, down $300 million at the top of that range. The results come a day after Moderna announced plans to slash 10% of its workforce, adding to a strin ...